Characterisation of recombinant HERG K+ channel blockade by the Class Ia antiarrhythmic drug procainamide

John M Ridley1, James T Milnes, Andrew V Benest

  • 1Department of Physiology and Cardiovascular Research Laboratories, School of Medical Sciences, University Walk, BS8 1TD, Bristol, UK

Insights

Procainamide (PROC) inhibits the HERG K(+) channel, a key factor in drug-induced arrhythmias. Its blocking potency is lower than other Class Ia drugs, suggesting structural differences influence HERG channel interactions.

Area of Science:

  • Cardiovascular pharmacology
  • Molecular electrophysiology
  • Ion channel research

Background:

  • Class Ia antiarrhythmic drugs, like procainamide (PROC), can cause pro-arrhythmia by affecting cardiac ion channels.
  • The HERG K(+) channel is implicated in drug-induced pro-arrhythmia.

Purpose of the Study:

  • To investigate the interaction between procainamide (PROC) and HERG K(+) channels.
  • To determine the potency and mechanism of PROC's action on HERG channels.

Main Methods:

  • Whole-cell patch-clamp recordings of HERG current (I(HERG)) in HEK 293 cells expressing HERG channels.
  • Application of activating pulses and varying membrane potentials to assess PROC's inhibitory effects.

Main Results:

  • PROC inhibited I(HERG) with an IC(50) of approximately 139 microM.
  • Blockade was time- and voltage-dependent, indicating interaction with open/activated HERG channel states.
  • Inhibition was reduced at highly positive potentials favoring HERG channel inactivation.

Conclusions:

  • PROC inhibits HERG K(+) channels primarily through an open/activated state block.
  • Reduced drug-binding avidity correlates with HERG channel inactivation.
  • PROC's lower potency compared to quinidine/disopyramide highlights structural determinants of HERG channel blockade.

Related Concept Videos

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...